Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 76 entries
View as:

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT04045145 Org: User:
Start: 12/12/19 End: 07/02/21 Due: 07/02/22

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03224325 Org: User:
Start: 07/21/17 End: 09/09/18 Due: 09/09/19

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03687684 Org: User:
Start: 10/09/18 End: 06/19/19 Due: 06/19/20

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT03891862 Org: User:
Start: 03/18/19 End: 01/30/20 Due: 01/30/21

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT03525886 Org: User:
Start: 04/10/18 End: 04/07/20 Due: 04/07/21

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Phase: N/A Priority: Normal
NCT ID: NCT04625101 Org: User:
Start: 04/26/21 End: 10/11/22 Due: 10/11/23

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05545111 Org: User:
Start: 10/04/22 End: 07/10/24 Due: 07/10/25

Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

Phase: N/A Priority: Normal
NCT ID: NCT04880616 Org: User:
Start: 04/20/21 End: 06/08/22 Due: 06/08/23

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

Phase: N/A Priority: Normal
NCT ID: NCT03562494 Org: User:
Start: 10/17/18 End: 10/30/24 Due: 10/30/25

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03065192 Org: User:
Start: 05/11/17 End: 08/10/21 Due: 08/10/22

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04234672 Org: User:
Start: 02/17/20 End: 04/04/20 Due: 04/04/21

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Phase: N/A Priority: Normal
NCT ID: NCT04806451 Org: User:
Start: 06/25/21 End: 08/31/27 Due: 08/31/28

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

Phase: N/A Priority: Normal
NCT ID: NCT02959892 Org: User:
Start: 12/05/16 End: 08/23/17 Due: 08/23/18

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Phase: N/A Priority: Normal
NCT ID: NCT03214588 Org: User:
Start: 11/08/17 End: 12/27/18 Due: 12/27/19

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03530293 Org: User:
Start: 04/17/18 End: 07/16/19 Due: 07/16/20

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT06963034 Org: User:
Start: 05/31/25 End: 10/31/27 Due: 10/31/28

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT03359785 Org: User:
Start: 01/10/18 End: 12/21/20 Due: 12/21/21

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT03319953 Org: User:
Start: 12/21/17 End: 11/06/19 Due: 11/06/20

Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT00079495 Org: User:
Start: 07/31/03 End: 04/30/05 Due: 04/30/06

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT05493293 Org: User:
Start: 11/09/22 End: 03/11/24 Due: 03/11/25

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Phase: N/A Priority: Normal
NCT ID: NCT04873869 Org: User:
Start: 01/31/22 End: 12/31/25 Due: 12/31/26

An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

Phase: N/A Priority: Normal
NCT ID: NCT00525941 Org: User:
Start: 09/30/07 End: 01/31/08 Due: 01/31/09

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05110157 Org: User:
Start: 11/29/21 End: 07/18/25 Due: 07/18/26

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01973543 Org: User:
Start: 10/31/13 End: 01/24/20 Due: 01/24/21

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Phase: N/A Priority: Normal
NCT ID: NCT05206513 Org: User:
Start: 04/15/22 End: 01/31/26 Due: 01/31/27